Head-to-head · WeighScore
NuuVim vs Welling Health
The verdict
NuuVim takes it — 71.1/100 to 68/100.
NuuVim grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuuVim is a Texas-based DTC telehealth program offering compounded semaglutide and tirzepatide in both injectable and oral forms — oral access is uncommon here — plus limited brand-name Ozempic and Zepbound.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | NuuVim | Welling Health |
|---|---|---|
| WeighScore | 71.1/100 | 68/100 |
| Grade | C | C |
| Scorecard rank | #101 | #159 |
| Semaglutide | $79/mo (all doses, compounded) | $190/mo (compounded) |
| Tirzepatide | $133/mo (all doses, compounded) | $275/mo (compounded) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #101 · C
Strengths
- Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
- Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
- LegitScript Certified and HIPAA-compliant
- Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
- Operating legal entity disclosed: NuuVim LLC, Texas governing law
Where it loses points
- No founder, CEO, medical director, or pharmacist-in-charge named
- Refund and cancellation policy not surfaced on the site
- Compounded medications are not FDA-approved
- Doesn't disclose which pharmacy fills which drug or form
- FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
Graded #159 · C
Strengths
- Transparent flat monthly rate — $190 semaglutide / $275 tirzepatide, all doses, no insurance or hidden fees
- LegitScript-certified 503A pharmacy with US-licensed clinicians in all 50 states and a named legal entity
- Streak discounts cut up to 30% — semaglutide as low as $133/month for logging meals consistently
- Free shipping, free AI macro-tracker app, and 24-hour intake review
Where it loses points
- Tirzepatide at $275/month is higher than the cheapest compounded competitors
- The streak discount requires daily in-app meal logging — miss days and you pay full rate
- The compounding pharmacy partner is described as a LegitScript-certified 503A but not named
- Only two medications — compounded semaglutide and tirzepatide; no oral or non-GLP options
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.